AstraZeneca Plans $50 Billion Investment in US Amid Tariff Threats

AstraZeneca has announced it will invest $50bn in the US by 2030. The British drugmaker plans to fund a new drug manufacturing facility in Virginia and expand its research and development in several states. This decision comes as Donald Trump threatens tariffs on pharmaceuticals made outside the US. The US commerce secretary praised AstraZeneca's move, emphasizing the creation of jobs and domestic production.

The company aims to achieve $80bn in revenue by 2030, with half of it coming from the US. AstraZeneca's investment aligns with other pharmaceutical firms like Roche, Novartis, and Johnson & Johnson, who have also announced significant investments in US manufacturing. The Trump administration is scrutinizing the industry due to concerns about national security and pricing practices.

Technology companies like Apple have also pledged substantial investments in the US. AstraZeneca's commitment follows reports of a potential stock market listing shift from London to New York, which could impact the UK market significantly.

According to the source: The Guardian.